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Abstract 
Although angiogenesis is a hallmark feature of asthmatic inflammatory responses, therapeutic 
anti-angiogenesis interventions have received little attention. Objective: Assess the effectiveness of 
anti-angiogenic Sn2 lipase-labile prodrugs delivered via αvβ3-micellar nanotherapy to suppress 
microvascular expansion, bronchial remodeling, and airway hyper-responsiveness in Brown Norway 
rats exposed to serial house dust mite (HDM) inhalation challenges. Results: Anti-neovascular 
effectiveness of αvβ3-mixed micelles incorporating docetaxel-prodrug (Dxtl-PD) or fumagillin-prodrug 
(Fum-PD) were shown to robustly suppress neovascular expansion (p<0.01) in the upper 
airways/bronchi of HDM rats using simultaneous 19F/1H MR neovascular imaging, which was 
corroborated by adjunctive fluorescent microscopy. Micelles without a drug payload (αvβ3-No-Drug) 
served as a carrier-only control. Morphometric measurements of HDM rat airway size (perimeter) and 
vessel number at 21d revealed classic vascular expansion in control rats but less vascularity (p<0.001) 
after the anti-angiogenic nanotherapies. CD31 RNA expression independently corroborated the 
decrease in airway microvasculature. Methacholine (MCh) induced respiratory system resistance (Rrs) 
was high in the HDM rats receiving αvβ3-No-Drug micelles while αvβ3-Dxtl-PD or αvβ3-Fum-PD micelles 
markedly and equivalently attenuated airway hyper-responsiveness and improved airway compliance. 
Total inflammatory BAL cells among HDM challenged rats did not differ with treatment, but αvβ3+ 
macrophages/monocytes were significantly reduced by both nanotherapies (p<0.001), most notably by 
the αvβ3-Dxtl-PD micelles. Additionally, αvβ3-Dxtl-PD decreased BAL eosinophil and αvβ3+ CD45+ 
leukocytes relative to αvβ3-No-Drug micelles, whereas αvβ3-Fum-PD micelles did not. Conclusion: 
These results demonstrate the potential of targeted anti-angiogenesis nanotherapy to ameliorate the 
inflammatory hallmarks of asthma in a clinically relevant rodent model. 
Key words: Asthma, Nanomedicine, Prodrug, Angiogenesis, Fluorine MRI, Respiratory function 
Introduction 
Asthmatic symptoms like bronchial 
hyper-responsiveness and overall reduced lung 
function reflect the underlying structural changes to 
the airway wall due to chronic inflammation.[1] 
Among the notable structural remodeling features of 
asthmatic airways is the long-recognized expansion of 
the bronchial vascular bed. Earlier research showed 
that alterations in bronchial blood flow or capacity in 
asthmatic patients were quantitatively reflected as 
changes in airway temperature. These changes in 
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airway temperature were unrelated to cardiac output 
or pulmonary blood flow, suggesting that they were 
associated with vascular expansion within the 
bronchial circulation. [2-6] Systemic vascular 
expansion in the lung is associated with macrophage 
activation, elaborating pro-angiogenic chemokines 
that stimulate neovascular expansion. [7, 8]  
 Anti-inflammatory systemic or inhaled 
corticosteroids are critical therapeutic drugs used in 
the acute and chronic management of asthma 
patients, which at higher doses elicit pleiotropic 
pharmacologic vascular remodeling effects including 
local vasoconstriction and inhibition of the production 
of pro-angiogenic cytokines and chemokines. [9-12] 
Neovastat, an anti-inflammatory marine cartilage 
derivative, suppressed airway inflammation 
associated with reductions in vascular endothelial 
growth factor (VEGF) and hypoxia-inducible 
factor–2α (HIF-2α) expression in murine lung tissue in 
ovalbumin-sensitized mice. [13] Despite the close 
interrelationship of airway inflammation and 
increased microvascularity, anti-angiogenesis 
treatment, such as anti-VEGF therapy, has not been 
considered, perhaps because such blockades can be 
circumvented by alternative pro-angiogenic factors 
and endothelial signaling pathways.   
 Fumagillin is a highly potent anti-angiogenic 
mycotoxin that inhibits methionine aminopeptidase-2 
in proliferating endothelial cells leading to 
apoptosis.[14, 15] In its stabilized water soluble form, 
designated TNP-470, it had anecdotal benefit in 
cancer patients but at the systemic doses required 
patients experienced mild to moderate neurocognitive 
side-effects. [16-21] Native fumagillin incorporated 
into the lipid encapsulated αvβ3-targeted 
nanoparticles markedly lowered the effective dose in 
preclinical cancer [22] and rheumatoid arthritis [23] 
models, which was further reduced when included as 
an Sn2 lipase labile phospholipid prodrug. [24, 25]  
 Paclitaxel, which interacts with tubulin also has 
anti-angiogenic benefit. [26] However, the off-target 
adverse profile of taxanes precludes their general 
systemic use as an anti-angiogenic therapeutic for 
asthma. Unlike native fumagillin, hydrophobic 
taxanes were not effectively retained in lipid 
encapsulated αvβ3-targeted nanoparticles during 
circulation except when modified into an Sn2 lipase 
labile prodrug. [27] Importantly, at an effective 
anti-angiogenic drug level of taxane administered as 
αvβ3-targeted Sn2 docetaxel prodrug nanoparticles in 
the Vx2 rabbit cancer model, Abraxane dosed iv was 
ineffective. [27]   
 In the present study, lipase labile phospholipid 
prodrug forms of fumagillin (Fum-PD) or docetaxel 
(Dxtl-PD) were incorporated into lipid-based micelles 
for targeted drug delivery in the context of asthma to 
determine if anti-angiogenesis nanotherapy could 
offer a new therapeutic approach to this serious 
disease. [25, 27-29] In general, lipase labile prodrugs 
inactivate chemotherapeutic compounds and prevent 
premature drug-loss from the nanoparticle during 
circulation. Sensitive functional groups of drugs are 
sequestered within the hydrophobic acyl membrane 
compartment and protected from the surrounding 
water milieu. [30] Lipid prodrugs are delivered by a 
mechanism termed “contact-facilitated drug delivery” 
(CFDD). [31] For CFDD the targeted cell surface 
receptor, e.g., αvβ3, is used as a “mooring” that allows 
the lipid nanoparticle surface to form an irreversible 
hemifusion complex with the target cell membrane. 
[32, 33] The prodrugs transfer spontaneously into the 
target cell outer and then inner membranes. The 
continuity of the inner cell membrane with 
intracellular membranes, except mitochondria, 
distributes the prodrugs throughout the cellular 
compartments. Within the cell a myriad of 
intracellular lipases can cleave the Sn2 ester of the 
lipid backbone, liberating and reactivating the 
compound within the cytosol. Direct targeting of 
proliferating neoendothelial cells with αvβ3-targeted 
Fum-PD or Dxtl-PD nanoparticles induces apoptosis. 
[24] 
 In this proof of concept study, the impact of 
anti-neovascular therapy was evaluated as a 
therapeutic regimen for asthma in a clinically relevant 
animal model. The temporal and spatial distribution 
of angiogenesis, vascularity, and airway reactivity in a 
Brown Norway rat model following serial allergen 
challenges with house dust mite (HDM) was recently 
characterized by Wagner et al. [34] Utilizing this 
model, the overarching objectives of this 
proof-of-concept study were: 1) to confirm the 
anti-angiogenic efficacy in asthma of αvβ3-targeted 
Fum-PD or Dxtl-PD micelles using MR simultaneous 
dual 19F/1H neovascular molecular imaging (3T); 2) to 
assess the impact of anti-angiogenesis therapy on 
airway hyper-reactivity and compliance response to 
methacholine challenge; 3) to delineate the impact of 
anti-angiogenesis treatment on airway vascular 
morphology and structural remodeling; and 4) to 
characterize the treatment effects on bronchial 
alveolar lavage cell numbers and type.  
Methods 
Preparation of Sn2 lipase labile fumagillin 
prodrug  
 A modified synthesis of the Sn2 prodrug was 
developed and accomplished in two steps [29]: 1) 
saponifying fumagillin dicyclohexylamine salt to 
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fumagillol, and 2) esterifying the product with 
1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine 
(PAzPC).[29] (Figure 1A) Briefly, fumagillin 
dicyclohexylamine salt (NCI) in 0.1N NaOH was 
stirred at ambient temperature (4h). The reaction 
mixture was extracted with ethyl ether (3X) and dried 
with anhydrous Na2SO4. After filtering the Na2SO4 the 
ether was evaporated to a yellow oil (yield ~60%). The 
final structure of fumagillol was confirmed by MS.  
 A solution of 1-hexadecyl-2-azelaoyl-sn- 
glycero-3-phosphocholine (Paz-PC, Avanti Polar 
Lipids) 1mM, 4-dimethylaminopyridine (DMAP)(5X) 
and N,N'-dicyclohexyl-carbodiimide (DCC) (5X) was 
added to 1mM fumagillol in minimal dry chloroform. 
The reaction mixture was stirred overnight at ambient 
temperature then passed over a short pad of silica gel 
using EtOAc/n-hexane (1:1). The filtered solvent was 
removed in vacuo, and the oil residue was purified by 
column chromatography on SiO2 using 
EtOAc/n-hexane for elution to yield the fumagillol 
prodrug (Fum-PD) compound as a pale yellowish 
solid (yield: 54%). Mass spectroscopy (MS) confirmed 
the final synthetic structure: m/z [C49H88NO13P, 
calculated mass= 929.60, observed= 930].  
Preparation of Sn2 lipase labile docetaxel 
prodrug  
 For the present research modified synthesis of 
docetaxel prodrug was developed. Docetaxel (Sigma 
Aldrich) dissolved in dimethylformamide (DMF) 0.02 
mmole/ml was combined with Paz-PC in chloroform 
(0.02 mmole/ml) then carbodiimide (DCC) / 
dimethylaminopyridine (DMAP) on silica was added. 
The mixture was incubated at room temperature 
overnight then filtered. The DMF was dried in vacuo 
to a solid. (Figure 1B) The compound was isolated 
and purified by preparative thin layer 
chromatography (prep-TLC) (50% yield) and the 
structure confirmed by NMR and ESI MS 
spectroscopy (Dxtl-PD: m/z [C76H115N2O23P, calculated 
mass=1454.76, observed M+H+=1456]).  
ανβ3-integrin antagonist homing ligand 
 The ανβ3-integrin antagonist was a quinalone 
nonpeptide developed by Bristol-Myers Squibb 
Medical Imaging (US patent 6,511,648 and related 
patents) and provided coupled to 
phosphatidylethanolamine through a polyethylene 
glycol2000 spacer (ανβ3-PEG-PE, Kereos, Inc., Figure 
1C). The antagonist was initially characterized as the 
111In-DOTA conjugate RP478 and cyan 5.5 homologue 
TA145.[35] PFC nanoparticles present ~300 
ligands/particle with an IC50 of 50 pM for the 
Mn2+-activated αvβ3-integrin. [36]  
The homing high specificity of 
ανβ3-nanoparticles (>150 nm nominal diameter) was 
previously characterized using microscopic histology 
of Matrigel™ plugs implanted into Rag1tm1Mom Tg 
(Tie-2-lacZ)182-Sato and C57Bl/6 mice [37], using 
photoacoustic molecular imaging of neovascular 
sprouting in a Matrigel™ plug model in rats [38], and 
in an ischemic left pulmonary artery ligation (LPAL) 
model of bronchial angiogenesis induction in rodents. 
[39] Robust reproducibility of serial targeting and MR 
molecular imaging within individual rabbits bearing 
Vx2 tumors over approximately one week was also 
reported. [40] 
Synthesis of αvβ3-integrin targeted therapeutic 
micelles  
 Therapeutic mixed micelles were prepared by 
microfluidization using 20% (v/v) polysorbate 80 
(NOF America), 2.0% (w/v) of a surfactant 
co-mixture, and 1.7% (w/v) glycerin suspension in 
carbonate buffer (pH 6.5). The surfactant co-mixture 
of nanoparticles included: 97.8 mole% lecithin and 0.2 
mole% of αvβ3-PEG-PE, and 2 mole% of Fum-PD or 
Dxtl-PD. Drug concentrations of the therapeutic 
micelles were equimolar (0.5mM). AlexaFluor™ or 
rhodamine dyes for fluorescent microscopy were 
coupled to PEG2000-PE lipid anchors (0.6 mole%) and 
included in the surfactant co-mixture at the equimolar 
expense of lecithin for fluorescent microscopy. 
“No-Drug” nanoparticles excluded the 2 mole% of 
Fum-PD or Dxtl-PD, which was replaced by lecithin. 
Surfactant components were combined with the 
polysorbate, buffer, and glycerin with pH adjusted to 
6.5, and the mixtures were homogenized at 20,000 psi 
for 4 minutes. The micelles were preserved under 
inert gas in sterile sealed vials until use.  
Synthesis of αvβ3-integrin targeted 
perfluorocarbon nanoparticles for MR imaging 
 Phospholipids-encapsulated perfluorocarbon 
(PFC) nanoparticles (NP) for neovascular MR 
molecular imaging were prepared as a microfluidized 
suspension of 20% (v/v) perfluoroctylbromide 
(PFOB, Exfluor Inc., Round Rock, TX), 2.0% (w/v) of a 
surfactant co-mixture, and 1.7% (w/v) glycerin in pH 
6.5 carbonate buffer as described above. The 
surfactant co-mixture of nanoparticles included: ~ 
99.8 mole% lecithin and 0.2 mole% of αvβ3-PEG-PE. 
Dyes, e.g. AlexaFluor™ or rhodamine, were coupled 
to PEG2000-PE lipid anchors (0.6 mole%) and included 
in the surfactant co-mixture at the equimolar expense 
of lecithin for fluorescent microscopy. Typical particle 
size determined by dynamic light scattering was 214 ± 
20 nm with a polydispersity index of 0.15 ± 0.5 and 
zeta potential, (ζ) of 23 ± 12 mV (Brookhaven 
ZetaPlus, Brookhaven Instruments Corporation).  
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MR neovascular imaging response to 
αvβ3-targeted Fum-PD and Dxtl-PD 
nanotherapy 
 Male Brown Norway rats (BN, Charles River, 
100 g) were administered house dust mite allergen 
(HDM, Der p 1; 100 µg/100µl challenge, Greer 
Laboratories) by intranasal inspiration, as previously 
reported [34] on days 0, 5 and 7 followed by i.v. 
αvβ3-No-Drug (n=6), αvβ3-Fum-PD (n=6) or 
αvβ3-Dxtl-PD (n=6) on days 6 and 8 (35µl, 0.7 
µmole/kg/dose to offset anticipated transbiliary 
losses in rodents). [41] All animals were studied using 
simultaneous dual 19F/1H MR neovascular imaging at 
3T (Achieva 3T, Philips Healthcare, Andover, MA). 
Animal protocols were approved by the Johns 
Hopkins and Washington University Animal Care 
and Use Committees. 
 On day 10, 2 days following the last 
anti-angiogenesis nanotherapy, all HDM treatment 
groups were administered αvβ3-PFOB NPs (35µl) via 
tail vein catheter. Two hours later, the animals were 
anesthetized with a non-fluorinated anesthetic 
(ketamine/xylazine; 85/13 mg/kg) and imaged with 
high-resolution simultaneous 19F/1H MRI using an 
in-house custom dual-tuned solenoid transmit-receive 
coil. Simultaneous 3D 19F/1H imaging was used 
employing a novel steady state ultra-short echo time 
(UTE) technique (TE/TR=0.1ms/1.96ms) with the 
frequencies set to the resonance of 1H and the CF2 
groups of the PFOB spectrum (offset 6328Hz from 19F; 
representing 12 of 17 total 19F nuclei). [42-45] Using a 
highly oversampled 3D radial readout scheme, a 
series of 19F images were reconstructed, post facto, by 
modifying the Nyquist weighting factor applied to 
samples in k-space. A Nyquist value that provided the 
optimal balance between the 19F signal-to-noise ratio 
(SNR) and image resolution was selected and that 
value was uniformly applied to each individual 
animal[46]. 1H images were used at the original 
resolution of 1.25x1.25x1.25 mm3. In this anesthetized 
rat model, neither mathematical correction nor 
respiratory gating were required to adjust for motion, 
as the breathing motion was of the same order of 
magnitude or less than the pixel resolution and any 
related ghosting was averaged out over the 28 min 
total scan time.  
19F/1H MR image analysis 
 MR data sets were imported into ImageJ (NIH) 
for quantification of the 19F signal. The method for 
measuring neovascularity was based upon the 
integral of 19F signal intensity from αvβ3-PFOB NPs. 
Lung regions of interest (ROIs) were defined from 
anatomical matching of multi-slice 1H and 19F MR 
datasets. These ROIs consistently included the heart 
in order to capture neovascularity located proximate 
to the trachea. To determine the background noise 
level, these same (size and shape) ROIs were 
repositioned in the upper left area of the image, 
devoid of any signal or potential respiratory-related 
ghosting. For each 19F 2D image slice, the average 
signal in this background ROI was calculated and 
subtracted from the image to standardize. Small 
experiment-to-experiment differences in absolute 
image intensity due to variations in RF coil tuning or 
animal position were referenced to a PFOB emulsion 
standard placed with the field of view adjacent to the 
animal. The normalized lung 19F signal was then 
averaged across all lung ROI slices.  
Microscopic imaging to corroborate MR 
neovascular imaging  
 In a separate cohort (n=3/treatment) treated 
identically to those animals used for 19F/1H MR 
molecular imaging, animals were euthanized 2 hours 
after injection of fluorescent αvβ3-PFOB NPs. Lungs 
were inflated to a pressure of 12 cmH2O and infused 
with warmed liquefied 1% agarose (42ºC). The upper 
airway, major bronchi, and surrounding tissue were 
resected and snap frozen in optimum cutting 
temperature (OCT) compound. Tissues were 
sectioned and fluorescent microscopic images (40x) 
were obtained with an Olympus BX61 microscope. 
Cell nuclei were stained blue with DAPI 
(4',6-diamidino-2-phenylindole, dihydrochloride). 
Pharmacokinetics of αvβ3-micelles in naive and 
HDM challenged Brown Norway rats 
 Male BN rats (100 g; n=6) were administered 
house dust mite allergen or PBS control by intranasal 
instillation on days 0, 5 and 7. On day 8, αvβ3-micelles, 
incorporating 2 mole% Gd-DTPA-bisoleate as a trace 
marker in the surfactant commixture, were injected 
via tail vein. Serial blood samples were drawn for 
pharmacokinetic analysis 0, 5, 15, 30, 45, 60, 90 and 
120 minutes post dose. Blood samples were analyzed 
for gadolinium using ICP OES (Optima 8000, 
Perkin-Elmer). The results were fit to a two 
compartmental model (Gd3+ concentration = A e-αt + B 
e-βt; GraphPad Prism 5.04). 
Pathological response to anti-angiogenesis 
nanotherapy in asthmatic Brown Norway rats 
 Using the sensitization protocol previously 
discussed [34], separate cohorts of male BN rats (BN, 
125-150 g) were given HDM allergen by intranasal 
instillation twice/week for 3 wks. Following the 
second HDM treatment each week, rats received 
αvβ3-No-Drug, αvβ3-Fum-PD (1.0 µmole/kg/dose), or 
αvβ3-Dxtl-PD (50µl, 1.0 µmole/kg/dose) by tail vein 
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injection (n=4 rats/group). Rats were studied one day 
after the last intranasal challenge of HDM.  
 For these animals, lungs were inflated with Z-fix 
(Anatech, Battle Creek, MI) to a pressure of 12 cmH2O 
for 24 hr. The left lung was divided into three sections, 
embedded in paraffin, and stained with hematoxylin 
and eosin (H&E). Airways (all cut in cross-section; 
max/min diameter ratio <1.5) were sized by basement 
membrane perimeter (ImageJ, NIH) and the number 
of blood vessels within the associated airway wall was 
enumerated. Morphometry was determined in lung 
sections from rats given αvβ3-No-Drug, αvβ3-Fum-PD, 
or αvβ3-Dxtl-PD micelles (n=4 rats/group).    
Airway smooth muscle responsiveness 
following anti-angiogenesis nanotherapy 
 Following the same HDM and micelle dosing 
regimen, male BN rats (n=6/treatment group) 
received αvβ3-No-Drug, αvβ3-Fum-PD, or 
αvβ3-Dxtl-PD micelles 1 day after the second weekly 
HDM instillation. After 3 weeks the rats were 
anesthetized (ketamine /xylazine, 75/5 mg/kg), 
intubated, and paralyzed (0.6 mg succinylcholine 
chloride) and dynamic respiratory mechanics were 
determined. Animals were ventilated (90 
breaths/min; 8 ml/kg) and lung resistance and 
compliance were measured (Scireq Flexivent). 
Following the baseline measurements, cumulative 
dose-response relationships to methacholine chloride 
(MCh) aerosol (15 sec with an Aeroneb nebulizer) at 
challenges of 0 (PBS vehicle), 0.1, 1.0, 3.0, and 5 
mg/ml MCh were obtained.  
RT-PCR of endothelial specific genes following 
anti-angiogenesis nanotherapy 
 Based on previous findings and according to the 
same procedures [34], CD31, an endothelial-related 
gene, was evaluated in large airways of HDM 
exposed rats given αvβ3-No-Drug (n=3), αvβ3-Fum-PD 
(n=4), or αvβ3-Dxtl-PD (n=4) micelles. Total RNA was 
isolated from homogenized tracheal tissue 
(RNeasy;Qiagen) according to the manufacturer’s 
protocol, cDNA was generated with QuantiTect 
Reverse Transcription kit (Qiagen; Real-Time PCR 
Detection System (Bio-Rad) settings and primers were 
as previously reported. [34] 
Bronchoalveolar lavage recovery and cytospin 
preparation 
 Immediately after death, bronchoalveolar lavage 
(BAL) was performed using three aliquots of warm 
(37oC) saline (2 ml / aliquot, 0.9% NaCl) delivered to 
the right lung and then gently aspirated (3-4 rats per 
treatment group). One ml of the recovered volume 
was separated and the cells were measured using a 
hemocytometer. Total cell numbers were 
back-calculated. BAL cells (5 x104) were spun onto 
glass slides by cyto-centrifugation, fixed and stained 
with HEMA 3 STAT PACK kit (Fisher Scientific, 
Kalamazoo, MI). The cytospin slides were 
differentiated by standard cytological procedures. 
FACS staining and flow cytometry of 
bronchoalveolar lavage cells 
 BAL fluid was withdrawn as described above 
and immediately centrifuged (1400 rpm, 5 min, 4°C). 
The cell pellet was resuspended in PBS for FACS 
staining. Dead cells were excluded using VIVID® 
(Invitrogen). Cells were blocked with anti-rat CD32 
(BD Pharmingen) and subjected to biotinylated 
anti-αvβ3 (eBioscience). Subsequent surface staining 
was performed using FITC anti-rat CD11c, Pacific 
Blue anti-rat CD11b (Bio-Rad), APC anti-rat ED-9 
(eBioscience), PE anti-rat MHC II (Santa Cruz) and 
APC/Cy7 anti-rat CD45 (Biolegend). Cells were 
acquired on a BD FACSAria (BD Biosciences) and 
data were analyzed with FlowJo software (Tree Star, 
Ashland, OR). 
Statistics 
 Imaging data were statistically analyzed using 
SAS (SAS Institute Inc.) using general linear models, 
including ANOVA and ANOCOV employing Tukey’s 
test for multiple comparisons for significant 
F-statistics. Group replication was powered to detect a 
50% or greater difference at an alpha level of 0.05 with 
a beta power of 0.80. [47] Least-squares regression 
was used to estimate the slopes of airway size 
(perimeter, mm) versus vessel number within 
treatment groups. Airway morphology data were 
analyzed with two-way ANOVA controlling for the 
within animal variability using Fisher’s LSD for mean 
separation. Means with a probability of difference ≤ 
0.05 were accepted as significant. All nominal data are 
presented as the mean ± the standard error of the 
mean. 
Results 
 Fum-PD and Dxtl-PD were synthesized by 
modification of prior procedures as described in the 
Methods section and illustrated schematically in 
Figure 1A,B, respectively. The αvβ3-peptidomimetic 
homing ligand utilized was provided as a gift (Kereos, 
Inc, St. Louis). (Figure 1C) αvβ3-mixed micelles used 
for drug delivery had nominal particle sizes of 16 ± 4 
nm and polydispersities between 0.1 and 0.2 based on 
dynamic light scattering (DLS) and an electrophoretic 
potential (ζ) of -20 ± 6 mV, across batches. Figure 1D 
presents a representative DLS distribution example 
for an αvβ3-Dxtl-PD micelle formulation. 
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 Pharmacokinetics of the αvβ3-micelles tagged 
with a gadolinium-lipid tracer was studied in HDM 
(n=3) and naïve rats (n=3) with no difference (p>0.05) 
appreciated between the two groups. The results fit to 
a two compartmental model (Gd3+ concentration = A 
e-αt + B e-βt) were in very close agreement and were 
pooled to provide alpha distribution half-life of 6.9 
min and a beta elimination half-life of 154.6 min 
estimates; the beta elimination rate unexpectedly 
exceeded the sampling regimen. (Figure 1E) 
 The early induction of bronchial 
neovascularization after ischemic left pulmonary 
artery ligation and HDM sensitization was previously 
validated and characterized using 19F/1H MR 
molecular imaging and corroborating histopathology 
and functional airway studies. [34, 39] 
Anti-angiogenesis treatment of the asthmatic HDM 
rats with αvβ3-Dxtl-PD or αvβ3-Fum-PD micelles 
markedly and equally reduced (p<0.01) airway 
neovascular MR signal when compared to asthmatic 
animals receiving αvβ3-No-Drug micelles. (Figure 
2A-C) The binding of the fluorescent αvβ3- 
perfluorooctylbromide nanoparticles (αvβ3-PFOB-NP) 
within the bronchus of an HDM rat following 
αvβ3-Fum-PD micelles nanotherapy versus the dense 
accumulation of αvβ3-PFOB-NP along the large 
airway following αvβ3-No-Drug micelles was readily 
differentiated. (Figure 2 D, E) Qualitatively the 
previously reported 19F signal intensities of 
non-asthmatic control rats were similar to the control 
19F imaging data in the present study. [34] 
 Anti-angiogenic MR molecular imaging results 
were corroborated by immunofluorescence 
microscopy. The sparse binding of the red fluorescent 
αvβ3-PFOB-NP within the bronchus of an HDM rat 
following αvβ3-Fum-PD micelle nanotherapy versus 
the dense accumulation of αvβ3-PFOB-NP along the 
large airway following αvβ3-No-Drug micelles was 
easily differentiated. (Figure 2 D, E) Red fluorescent 
αvβ3-micelles accumulated within the HDM inflamed 
bronchus and surrounding parenchyma, whereas 
these particles administered to naïve rats (i.e., no 
HDM treatment) had negligible binding within or 
around the large pulmonary airways or vasculature. 
(Figure 2F,G) Collectively, the results corroborate the 
tomographic changes observed with 19F/1H MR 
neovascular imaging with αvβ3-PFOB NP and showed 
that integrin-targeted Fum-PD or Dxtl-PD micelles 
effectively diminished angiogenesis in HDM rats.  
 
 
Figure 1. A. Scheme 1 Synthesis of fumagillin (fumagillol) PAz-PC prodrug. B. Scheme 2 Synthesis of docetaxel prodrug. C. Structure 
αvβ3-peptidomimetic-PEG2000-PE. D. Example of dynamic light scattering micelle particle size distribution (αvβ3-Dxtl-PD). E. Averaged pharmacokinetic profile of 
αvβ3-micelles containing a Gd3+-lipid marker in the surfactant commixture. The two compartment model Gd3+ concentration (C) = A e-αt + B e-βt revealed an alpha 
distribution half-life of 6.9 min and a beta elimination half-life of 154.6 min. 
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Figure 2. A, B. 19F/1H MR molecular following anti-angiogenesis treatment in HDM rats with αvβ3-Dxtl-PD (right) revealed markedly reduced airway neovascular MR 
signal when compared to the control asthmatic animals receiving αvβ3-No-Drug micelles (left). C. Histogram of 19F/1H MR tomographic molecular imaging results 
showing equivalent reduction in neovascularity with anti-angiogenesis micelles (P<0.01). D. Sparse binding of the red fluorescent αvβ3-PFOB NPs within the bronchus 
of an HDM rat following αvβ3-Fum-PD micelles nanotherapy. E. Heavy accumulation of red fluorescent αvβ3-PFOB NPs along the large airway following αvβ3-No-Drug 
micelles. F. Red fluorescent αvβ3-micelles accumulated heavily within the HDM inflamed bronchus and surrounding parenchyma. G. Red fluorescent αvβ3-micelles 
administered to naïve rats (i.e., no HDM treatment) had negligible nonspecific binding. Green autofluorescence was noted in the airway and vascular walls. 
 
 Progressive HDM inhalation over three weeks in 
the Brown Norway rats was previously associated 
with increased (p<0.05) airway vascularity 
measurable with microscopy. [34] Gross airway and 
vascular casts demonstrated increased vascularity in 
HDM compared to control (PBS) rats after 3 wks of 
sensitization. In that study, 3 wks of HDM 
sensitization elicited an abundance of blood vessels 
within the airway wall compared to a paucity of 
bronchial vessels observed in the control bronchi. 
Striking differences in the influx of inflammatory 
cells, airway wall thickening, and smooth muscle 
contraction were noted in the HDM rats relative to the 
PBS controls. Further, the correlation slopes of airway 
size (perimeter, mm) versus the number of vessels 
normalized for airway area were different between 
HDM and PBS rats (p=0.002) and reflected increased 
numbers of vessels in HDM rats compared to PBS rats 
over an equivalent size range of airways studied 
(0.5-3mm).  
 These asthmatic changes were recapitulated at 
three weeks in the present study. The anti-angiogenic 
impact of serial αvβ3-Dxtl-PD or αvβ3-Fum-PD 
micelles after HDM inhalation demonstrated by MRI 
on day 10 was associated with profound attenuation 
of airway vascularity at 21 days. Least-squares 
regression slopes of airway size (perimeter, mm) 
versus vessel number significantly differed among 
treatment groups (p<0.001). Control HDM rats had 
more vessels as revealed by the slope (4.9 ± 0.5) than 
those receiving αvβ3-Dxtl-PD micelles (2.7 ± 0.3) or 
αvβ3-Fum-PD micelles (3.8 ± 0.5), (p<0.001). Further, 
the regression slope of αvβ3-Dxtl-PD micelle response 
was lower than the αvβ3-Fum-PD micelle observation. 
(p=0.0394). (Figure 3A) After normalizing vessel 
number for airway size (i.e., diameter), both 
αvβ3-Dxtl-PD (p<0.001; n=41 airways) and 
αvβ3-Fum-PD (p<0.001; n=45 airways) micelles 
decreased vascularity to a similar extent relative to the 
HDM rats receiving αvβ3-No-Drug micelles (n=55 
airways). (Figure 3B)  
 The marked morphometric vascular changes 
were corroborated by examining the RNA expression 
of endothelial-specific genes in tracheal tissue. The 
tracheal expression of CD31, a common biomarker of 
nascent and mature endothelial cells, was determined 
and compared to naïve tissue expression levels. 
(Figure 3C) CD31 expression was markedly decreased 
in large airway tissue after αvβ3-Dxtl-PD and 
αvβ3-Fum-PD micelle treatment compared to the 
HDM rats given αvβ3-No-Drug micelles (p<0.001).  
 Lung functional changes, a clinical hallmark of 
asthma, were assessed in a separate cohort of HDM 
rats that received αvβ3-Dxtl-PD, αvβ3-Fum-PD or 
αvβ3-No-Drug micelles. Respiratory system resistance 
(Rrs) was measured after increasing methacholine 
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(MCh) concentrations in each group. (Figure 4A) 
Airway reactivity to MCh was markedly attenuated 
among rats treated with αvβ3-Dxtl-PD or 
αvβ3-Fum-PD micelles compared with HDM rats 
receiving αvβ3-No-Drug particles (p<0.001), which 
was equivalent to the resistance response reported for 
naive rats previously. MCh airway responsiveness 
did not differ between the αvβ3-Dxtl-PD or 
αvβ3-Fum-PD nanotherapies. Respiratory system 
compliance (Crs) in HDM rats following the 3mg 
MCh challenge was greater after the anti-angiogenic 
nanotherapies than in the αvβ3-No-Drug micelle 
group (p<0.001) (Figure 4B). Airway smooth muscle 
thickening correlates with response to MCh, but 
additional morphological measurements were not 
obtained to reconfirm this relationship in this study.  
  Bronchoalveolar (BAL) cell profiles were 
compared among HDM rats receiving αvβ3-No-Drug 
micelles versus the αvβ3-Dxtl-PD or αvβ3-Fum-PD 
micelle treatments. Total inflammatory cells 
recovered were similar (p>0.05) between the groups 
at 3 weeks. (Figure 5A) BAL cell differential profiles 
among animals receiving αvβ3-Dxtl-PD micelles had a 
lower (p<0.05) percentage of eosinophils compared to 
HDM rats receiving αvβ3-Fum-PD or αvβ3-No-Drug 
treatments. (Figure 5B) Further, αvβ3-Dxtl-PD 
nanotherapy decreased αvβ3+ CD45+ leukocytes 
(p<0.001) whereas αvβ3-Fum-PD and αvβ3-No-Drug 
treatments had no effect. (Figure 5C) BAL flow 
cytometry showed that both αvβ3-Fum-PD and 
αvβ3-Dxtl-PD micelle treatments decreased (p<0.001) 
αvβ3+ macrophage/monocyte numbers versus the 
control micelles (Figure 5D). 
 
 
 
Figure 3. A. Least-squares regression slopes of airway size (perimeter, mm) versus vessel number significantly differed among treatment groups (p<0.001). Control 
HDM (●) rats receiving αvβ3-No-Drug had more blood vessels as revealed by the slope (4.9 ± 0.5) than those receiving αvβ3-Dxtl-PD micelles (2.7 ± 0.3, ◻) or 
αvβ3-Fum-PD micelles (3.8 ± 0.5, ▲), (p<0.001). Further, the regression slope of αvβ3-Dxtl-PD micelle response was lower than the αvβ3-Fum-PD micelle 
observation. (p=0.0394). B. After normalizing vessel number for airway size (i.e., diameter), both αvβ3-Dxtl-PD (p<0.0001) and αvβ3-Fum-PD (p<0.0003) micelles 
decreased vascularity to a similar extent relative to the HDM rats receiving αvβ3-No-Drug micelles (n=4 rats/group; 2-way ANOVA and Fisher’s LSD). C. CD31 
expression in the trachea of the three treatment groups compared to naïve tissue. Gene expression for CD31, a common endothelial cell marker, was markedly 
decreased in large airway tissue (trachea) after αvβ3-Dxtl-PD and αvβ3-Fum-PD compared to αvβ3-No-Drug (p=0.0005). 
 
Figure 4. Pulmonary functional changes in HDM rats receiving αvβ3-Dxtl-PD, αvβ3-Fum-PD or αvβ3-No-Drug micelles. A. Respiratory system resistance (Rrs) was 
measured after increasing methacholine (MCh) concentrations showing markedly attenuated reactivity among rats treated with αvβ3-Dxtl-PD or αvβ3-Fum-PD 
micelles. (*** p <0.001). B. Respiratory system compliance (Crs) in HDM rats following the 3mg MCh challenge showing greater compliance after the anti-angiogenic 
nanotherapies. 
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Figure 5. Bronchoalveolar (BAL) cell profiles. A. Total inflammatory cells recovered were similar between the groups at 3 weeks. B. BAL cell differential profiles 
showed a lower (p<0.05) percentage of eosinophils (EOS) in HDM rats receiving αvβ3-Dxtl-PD micelle than αvβ3-Fum-PD or αvβ3-No-Drug treatments. C. 
αvβ3-Dxtl-PD nanotherapy decreased αvβ3+ CD45+ leukocytes (p<0.001) whereas αvβ3-Fum-PD and αvβ3-No-Drug treatments had no effects. D. BAL flow cytometry 
revealing that αvβ3-Fum-PD and αvβ3-Dxtl-PD micelle treatments decreased (p<0.001) αvβ3+ macrophage/monocyte numbers versus the control micelles 
(αvβ3-Dxtl-PD > αvβ3-Fum-PD micelles). 
 
Discussion 
Structural remodeling of asthmatic airways has 
long been associated with microvascular expansion of 
the capillary bed. Although angiogenesis is a 
hallmark feature of asthmatic inflammatory 
responses, specific therapeutic anti-angiogenesis 
interventions have not been considered. In the present 
studies, anti-angiogenic prodrug therapeutics 
delivered by a micelle therapy markedly suppressed 
microvascularity, bronchial remodeling, and airway 
hyper-responsiveness in HDM rats, suggesting for the 
first time that direct anti-neovascular therapy can 
contribute significantly to asthma management.  
 The bioactivity and effectiveness of Sn2 lipase 
labile prodrugs of Dxtl and Fum delivered via 
αvβ3-integrin targeted micelles in HDM rats was 
definitively demonstrated noninvasively with 19F/1H 
MR neovascular molecular imaging using 
vascular-constrained αvβ3-PFOB nanoparticles and a 
clinical 3T scanner. The spatial and temporal character 
of neovascular expansion within the upper 
airways/bronchi of the HDM rats given 
αvβ3-No-Drug micelles recapitulated the 19F/1H MR 
response previously reported at this field strength. 
[34] However, the neovascular signal among rats 
receiving αvβ3-Dxtl-PD micelles or αvβ3-Fum-PD was 
greatly reduced, validating that the prodrugs retained 
drug bioactivity and that αvβ3-micelles effectively 
homed and bound to the neovasculature. These 
19F/1H MR imaging results were corroborated by 
immunofluorescent microscopic studies that also 
delineated the differential targeting of fluorescent 
αvβ3-PFOB nanoparticles (red) in HDM rats receiving 
αvβ3-No-Drug and αvβ3-Dxtl-PD micelles. The 
targeting of fluorescent αvβ3-micelles (red) into the 
airway wall and local surrounding tissue in No-Drug 
treated HDM rats but not in naïve animals is 
congruent with the therapeutic effects measured.  
 Within this study, MR provided early 
recognition of HDM induced airway inflammation as 
reflected by neovascular expansion and provided a 
quantitative read-out of anti-angiogenic treatment 
response. In the broader context, this result and 
previous reports of clinical 19F/1H MR molecular 
imaging of the lung pose the prospect for more 
detailed and quantitative image guided management 
of asthma patients, particularly those with moderate 
to severe disease. The workhorse imaging modality of 
lung imaging is computed tomography (CT) and for 
cancer is positron emission tomography/CT 
(PET/CT). As healthcare costs associated with newer 
biological precision medicine therapies soar for 
patients with moderate and particularly severe 
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asthma, improved high-sensitivity noninvasive 
nonionizing imaging to optimize and minimize the 
use of these therapies will be welcome. [48-51] 
Anticipating that repeat imaging studies will be used 
in pediatric patients as well as adults, the 
implementation of MRI techniques becomes highly 
attractive and circumvents potential cumulative X-ray 
risks. 
 Increased vascular density in the sub-epithelial 
submucosa of the lungs of asthmatic patients as well 
as other bronchial vasculature abnormalities is well 
documented and associated with increased blood 
flow and edematous airway thickening. [52] After 3 
weeks of biweekly HDM challenges, morphometric 
measurements of airway size (perimeter) and vessel 
number revealed classic asthma-related vascular 
expansion in the HDM rats receiving αvβ3-No-Drug 
micelles. HDM rats given the anti-angiogenic 
αvβ3-Dxtl-PD or αvβ3-Fum-PD micelle therapies had 
dramatically less microvascularity, which was 
confirmed by reduced CD31 RNA expression in these 
animals compared to the αvβ3-No-Drug controls.  
 Increased vascularization was previously 
correlated with airflow limitation and bronchial 
hyper-responsiveness. [12, 53, 54] In the present 
study, MCh induced respiratory system resistance 
(Rrs) was high in the HDM rats receiving the 
αvβ3-No-Drug particles but markedly and 
equivalently attenuated among rats treated with 
αvβ3-Dxtl-PD or αvβ3-Fum-PD micelles. Similarly, 
respiratory system compliance (Crs) was increased 
among HDM rats exposed to anti-angiogenic prodrug 
nanotherapy compared with the No-Drug micelles. 
Clearly, the relationship between airway 
hyper-responsiveness and vascularity observed in 
patients was observed in the HDM rat model, and by 
extension the substantial improvements elicited by 
αvβ3-Dxtl-PD or αvβ3-Fum-PD micelles in HDM rats 
could reasonably translate into patients. 
 As expected, microscopic examination revealed 
marked increases in inflammatory cells in HDM rat 
airways and surrounding tissues that were not 
appreciated in the lungs from control animals. 
Increased αvβ3-integrin expression heavily 
co-localized with activated macrophages by 
microscopy was also appreciated in BAL cells of 
control HDM. However, αvβ3+ macrophages were 
significantly reduced by both targeted nanotherapies 
and significantly more so by the αvβ3-Dxtl-PD micelle 
treatment. Anti-angiogenic therapy is typically 
viewed from the perspective of neovasculature 
pruning, but recent studies intensively examining the 
effects of αvβ3-Fum-PD in inflammatory mouse 
models have shown that direct anti-angiogenesis 
therapy is also anti-inflammatory. [24] 
Fumagillin is well known to impact the 
proliferation of neovascular endothelial cells, but this 
mycotoxin has negligible effects on non-endothelial 
cell types. [55] The overall outcome of a series of 
detailed experiments to delineate the potential 
mechanism for local inflammation suppression with 
integrin-targeted fumagillin determined that 
endothelial nitric oxide (NO) derived and released 
from the drug-targeted neoendothelial cells 
modulated local macrophage inflammatory response 
through AMP-activated protein kinase (AMPK). 
NO-induced AMPK activation decreased the 
mammalian target of rapamycin (mTOR) activity and 
increased autophagic flux, as evidenced by p62 
depletion and increased autolysosome formation. 
Increased macrophage autophagy flux was associated 
with degradation of IkappaB kinase (IKK), 
suppression of the NF-ĸB-p65 signaling pathway, and 
ultimately decreased inflammatory cytokine release. 
[24] Thus, the anti-inflammatory impact of Fum-PD 
was indirectly mediated through the endothelial NO 
release with suppressive feedback on the local 
macrophages. 
αvβ3-micelles, similar in size to IgG antibodies, 
penetrate into inflamed tissue readily. These micelles 
can home and bind to extravascular targets [56], 
including macrophages expressing activated 
αvβ3-integrin. Fum-PD is ineffective when 
co-incubated with activated macrophages in culture, 
but it is effective against vascular tubule formation in 
vitro. [24, 57] Dxtl-PD can suppress macrophage 
inflammatory cytokine release in vitro and in vivo, as 
well as being anti-angiogenic [30] (Supporting 
Information: S1). In the present study, αvβ3-Dxtl-PD 
micelles, in addition to the anti-angiogenic 
anti-inflammatory effects elicited by targeting 
neoendothelial cells similar to αvβ3-Fum-PD micelles, 
they likely bound phagocytic cells, possibly the M2 
phenotype macrophages increased in 
antigen-induced asthma. Of note in breast cancer, M2 
macrophages uniquely express activated 
αvβ3-integrin. [58] 
αvβ3-Dxtl-PD micelles but not αvβ3-Fum-PD 
micelles reduced BAL αvβ3+ CD45+ cells, probably as a 
direct consequence of targeted taxane prodrug 
delivery. This would be expected due to the 
endothelial cellular specificity of fumagillin. BAL 
eosinophils were generally elevated in the HDM rats, 
but markedly reduced among animals receiving 
αvβ3-Dxtl-PD micelles and not the αvβ3-Fum-PD 
micelles. Since αvβ3-integrin expression by eosinophils 
is uncommon, we hypothesize that the reduction of 
eosinophils was related to αvβ3-Dxtl-PD impacting M2 
macrophages within a complex 
Th1/Th2-macrophage-eosinophil cross-talk network. 
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[59-61] Further delineation of these complex 
interrelationships is beyond the scope of this initial 
study.  
 While the present report has shown for the first 
time that targeted αvβ3-micelle nanotherapy can 
ameliorate bronchial airway hyper-reactivity and 
inflammatory characteristics of dust-mite induced 
asthma in rats, specific mechanistic studies will be 
required to deconvolve the disruption of the complex 
roles of cellular inflammatory components and 
chemokines involved in the pathologic remodeling 
within the inflamed airways. Further, these data 
demonstrate that HDM induced asthma can be 
approached in a nontraditional therapeutic fashion, 
additional research to optimize the pharmacology and 
to elucidate the safety of this targeted therapeutic 
micelle approach is warranted. 
Conclusion  
 The results of this study clearly indicate that 
direct anti-angiogenesis therapy with αvβ3-Dxtl-PD or 
αvβ3-Fum-PD micelles can ameliorate asthma in the 
house dust mite triggered Brown Norway rat model. 
Airway hyper-responsiveness and increased 
microvascularity, classic hallmarks of asthma, were 
significantly reduced with these treatments. Whereas 
the dogma of efficacy surrounding anti-angiogenesis 
therapy has been associated with the impact of 
vascular pruning, in the current study αvβ3-Dxtl-PD 
or αvβ3-Fum-PD micelles treatment of proliferating 
neoendothelial cells led to secondary 
anti-inflammatory benefits.  
Supplementary Material  
Supporting Information S1.  
http://www.thno.org/v07p0377s1.pdf   
Abbreviations 
3D: three dimensional 
αvβ3: alpha v beta 3 integrin 
AMPK: adenosine monophosphate (AMP)-activated 
protein kinase 
ANOVA: analysis of variance 
ANOCOV: analysis of covariance 
APC: allophycocyanin 
BAL: bronchoalveolar lavage 
CD11b: cluster of differentiation 11 - antigen on 
monocytes/macrophages and microglia 
CD45: cluster of differentiation 11 - lymphocyte 
common antigen 
CD31: cluster of differentiation 31 - Platelet 
endothelial cell adhesion molecule (PECAM) 
CD32: cluster of differentiation 32 – Fc gamma 
receptor on B-cells 
CFDD: contact-facilitated drug delivery 
Crs: respiratory system compliance  
CT: computed tomography 
Cy7: cyanine7 - near infrared fluorescent dye 
DAPI: 4',6-diamidino-2-phenylindole  
DCC: carbodiimide 
DMAP: dimethylaminopyridine 
DMF: dimethylformamide 
DOTA: tetraazacyclododecane-1,4,7,10-tetraacetic acid 
DTPA: diethylenetriaminepentaacetic acid 
Dxtl-PD: docetaxel-prodrug 
ESI: electrospray ionization 
FACS: fluorescence-activated cell sorting 
FITC: fluorescein isothiocyanate 
FOV: field of view 
Fum-PD: fumagillin-prodrug 
HDM: house dust mites 
HIF-2α: hypoxia-inducible factor–2α 
ICP-OES: inductively coupled plasma optical 
emission spectrometry 
IKK: IkappaB kinase  
MCh: Methacholine 
MR: magnetic resonance 
MS: mass spectroscopy 
mTOR: mammalian target of rapamycin 
NCI: National Cancer Institute 
NF-ĸB: nuclear factor kappa-light-chain-enhancer of 
activated B cell 
NFkB-p65: a subunit of NF-kappa-B transcription 
complex 
NMR: nuclear magnetic resonance 
NO: nitric oxide 
OCT: optimum cutting temperature 
p62: nucleoporin p62 is a protein complex associated 
with the nuclear envelope 
PAzPC: 
palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine  
PBS: phosphate buffered saline 
PE:  phosphatidylethanolamine 
PEG: polyethylene glycol 
PET/CT: positron emission tomography/CT 
PFOB: perfluorooctylbromine 
psi: pounds per square inch 
RF: radio frequency 
RNA: ribonucleic acid 
ROI: regions of interest  
Rrs: respiratory system resistance  
Sn2: stereospecific numbering-by convention the 
hydroxyl group of the second carbon of glycerol  
T: Tesla  
TE: echo time 
TR: repetition time 
TNP-470: synthetic analog of fumagillin 
UTE: ultra-short echo time  
VEGF: vascular endothelial growth factor 
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